Last reviewed · How we verify
SoluMedrol
SoluMedrol (methylprednisolone sodium succinate) is a corticosteroid that suppresses the immune system and reduces inflammation by inhibiting inflammatory mediators and immune cell activation.
SoluMedrol (methylprednisolone sodium succinate) is a corticosteroid that suppresses the immune system and reduces inflammation by inhibiting inflammatory mediators and immune cell activation. Used for Acute inflammation and immune-mediated conditions (e.g., multiple sclerosis exacerbations, spinal cord injury, severe allergic reactions), Rheumatoid arthritis and other autoimmune disorders, Cerebral edema.
At a glance
| Generic name | SoluMedrol |
|---|---|
| Also known as | Corticosteroids, 6-Methylprednisolone, Methylprednisolone Acetate, Methylprednisolone Sodium Succinate, Methylprednisolone |
| Sponsor | University of Utah |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Neurology |
| Phase | FDA-approved |
Mechanism of action
Methylprednisolone is a synthetic glucocorticoid that binds to glucocorticoid receptors in the cytoplasm, translocates to the nucleus, and modulates gene expression to decrease production of pro-inflammatory cytokines, chemokines, and adhesion molecules. This results in broad immunosuppression and anti-inflammatory effects across multiple cell types and tissues.
Approved indications
- Acute inflammation and immune-mediated conditions (e.g., multiple sclerosis exacerbations, spinal cord injury, severe allergic reactions)
- Rheumatoid arthritis and other autoimmune disorders
- Cerebral edema
- Organ transplant rejection prophylaxis
Common side effects
- Hyperglycemia
- Hypertension
- Insomnia
- Mood changes (euphoria, anxiety)
- Immunosuppression / increased infection risk
- Gastrointestinal upset
Key clinical trials
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas (PHASE4)
- Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction (PHASE2)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |